We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
Read MoreHide Full Article
Key Takeaways
DXCM's G7 shows strong results in the CONNECT trial, supports CGM use in non-insulin-treated Type 2 diabetes.
DXCM's G7 users achieve a 1.6% A1C reduction and spend five additional hours daily within the target range.
Dexcom's CONNECT study shows 97% CGM use at 26 weeks, strengthening evidence for broader adoption.
DexCom, Inc. (DXCM - Free Report) recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the benefits of its Dexcom G7 continuous glucose monitoring (CGM) system in adults with Type 2 diabetes who are not using insulin, adding to the clinical evidence supporting broader CGM adoption.
The findings are encouraging for DexCom, as stronger clinical evidence could help expand CGM adoption among people with Type 2 diabetes who are not on insulin. Wider physician acceptance and improved insurance coverage could create additional growth opportunities for the company. However, the extent to which the study translates into higher sales will depend on physician adoption, reimbursement support and patient uptake.
More on the News
The CONNECT study screened 440 participants across 22 primary care sites in the United States, with 283 eligible adults randomized to receive either Dexcom G7 or routine care over 26 weeks. Participants using the CGM system achieved an average A1C reduction of 1.6% from a baseline of 8.8%, representing a 0.9-percentage-point greater reduction than routine care. At 26 weeks, 68% of Dexcom G7 users achieved an A1C below 7.5%, while 46% reached below 7.0%.
The group also spent approximately five additional hours per day within the target glucose range of 70-180 mg/dL, with improvements emerging within the first week of use. Benefits were observed across several demographic and clinical characteristics, including age, diabetes duration and glucose-lowering treatments. Among participants using GLP-1 therapies, DexCom G7 delivered an additional 0.9-percentage-point A1C reduction compared with routine care. Notably, 97% of participants were still using CGM after 26 weeks, with most using it daily. The findings were first presented at the American Diabetes Association's 2026 Scientific Sessions and strengthen the clinical evidence supporting CGM use among adults with Type 2 diabetes who are not using insulin.
The publication is particularly relevant because it provides evidence supporting earlier CGM use in Type 2 diabetes management, potentially expanding the addressable market beyond patients who require insulin. The study's results may encourage more physicians to recommend continuous glucose monitoring and strengthen discussions around reimbursement and broader patient access. However, translating these findings into sustained revenue growth will depend on adoption rates, payer coverage and affordability. The study also adds to the clinical evidence supporting Dexcom's G7 platform, although longer-term data will be important in assessing the durability of the observed benefits.
Recent Development by DXCM
Recently, DXCM released its 2026 “State of Type 2 Report: Global Access and Attitudes to Diabetes Technology” ahead of the 62nd Annual Meeting of the European Association for the Study of Diabetes. The report highlights significant gaps in CGM awareness and access while pointing to growing potential for combining CGM with GLP-1 therapies. Dexcom also partnered with Team Novo Nordisk, an all-diabetic professional cycling team primarily sponsored by Novo Nordisk, underscoring its focus on expanding CGM awareness and adoption.
DXCM’s Industry Prospects
According to Grand View Research, the global CGM devices market size was valued at $13.4 billion in 2025 and is projected to grow beyond $41.4 billion by 2033, at a CAGR of 15.1% from 2026 to 2033.
The primary driver of market growth is the rising global prevalence of diabetes, which has increased demand for more efficient, real-time glucose monitoring solutions.
Updates From DXCM Peers
Abbott Laboratories (ABT - Free Report) recently reported new real-world evidence supporting the benefits of CGM technology, including its FreeStyle Libre systems, for adults with Type 2 diabetes using basal insulin. According to studies, CGM use was associated with a 45% lower risk of death at 12 months and a 36% lower risk at 24 months.
A separate French observational study involving more than 253,000 people with Type 2 diabetes found that Abbott's Libre technology was associated with lower hospitalization rates for acute diabetes-related events across different treatment groups. These findings strengthen the clinical evidence supporting CGM adoption and could help ABT expand the reach of its diabetes care portfolio.
Medtronic (MDT - Free Report) recently completed the exchange-offer process for its diabetes business, MiniMed Group and announced final results on Oct. 14, 2026. The offer was oversubscribed, and Medtronic exchanged its remaining 252.8 million MiniMed shares for approximately 55 million Medtronic ordinary shares. Following the transaction, Medtronic will no longer retain an ownership stake in MiniMed, which is expected to operate as an independent publicly traded company.
The separation marks a strategic shift for Medtronic, allowing it to focus more closely on its remaining medical technology businesses, while MiniMed will pursue growth in diabetes care as a standalone company. The development is relevant to the competitive landscape for diabetes devices, although its longer-term impact will depend on MiniMed's performance as an independent business.
Insulet (PODD - Free Report) announced enhancements to its Omnipod 5 automated insulin delivery system in June 2026, alongside expanded compatibility with Abbott's FreeStyle Libre 3 Plus sensor in the United States. The upgraded algorithm introduces a 100 mg/dL target glucose setting and improved alarm handling, aiming to improve time in range and help users spend more time in automated mode. The expanded sensor compatibility also gives users greater flexibility in choosing their diabetes management technology. Separately, Insulet reported second-quarter 2026 revenues of $801.7 million, up 23.5% year over year, with Omnipod revenue increasing 24.6%.
These developments highlight continued product innovation and commercial momentum, which could support Insulet's growth in automated insulin delivery. However, sustained performance will depend on continued adoption, international expansion and execution in an increasingly competitive diabetes technology market.
View the Zacks #1 Rank List
Image: Bigstock
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
Key Takeaways
DexCom, Inc. (DXCM - Free Report) recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the benefits of its Dexcom G7 continuous glucose monitoring (CGM) system in adults with Type 2 diabetes who are not using insulin, adding to the clinical evidence supporting broader CGM adoption.
The findings are encouraging for DexCom, as stronger clinical evidence could help expand CGM adoption among people with Type 2 diabetes who are not on insulin. Wider physician acceptance and improved insurance coverage could create additional growth opportunities for the company. However, the extent to which the study translates into higher sales will depend on physician adoption, reimbursement support and patient uptake.
More on the News
The CONNECT study screened 440 participants across 22 primary care sites in the United States, with 283 eligible adults randomized to receive either Dexcom G7 or routine care over 26 weeks. Participants using the CGM system achieved an average A1C reduction of 1.6% from a baseline of 8.8%, representing a 0.9-percentage-point greater reduction than routine care. At 26 weeks, 68% of Dexcom G7 users achieved an A1C below 7.5%, while 46% reached below 7.0%.
The group also spent approximately five additional hours per day within the target glucose range of 70-180 mg/dL, with improvements emerging within the first week of use. Benefits were observed across several demographic and clinical characteristics, including age, diabetes duration and glucose-lowering treatments. Among participants using GLP-1 therapies, DexCom G7 delivered an additional 0.9-percentage-point A1C reduction compared with routine care. Notably, 97% of participants were still using CGM after 26 weeks, with most using it daily. The findings were first presented at the American Diabetes Association's 2026 Scientific Sessions and strengthen the clinical evidence supporting CGM use among adults with Type 2 diabetes who are not using insulin.
The publication is particularly relevant because it provides evidence supporting earlier CGM use in Type 2 diabetes management, potentially expanding the addressable market beyond patients who require insulin. The study's results may encourage more physicians to recommend continuous glucose monitoring and strengthen discussions around reimbursement and broader patient access. However, translating these findings into sustained revenue growth will depend on adoption rates, payer coverage and affordability. The study also adds to the clinical evidence supporting Dexcom's G7 platform, although longer-term data will be important in assessing the durability of the observed benefits.
Recent Development by DXCM
Recently, DXCM released its 2026 “State of Type 2 Report: Global Access and Attitudes to Diabetes Technology” ahead of the 62nd Annual Meeting of the European Association for the Study of Diabetes. The report highlights significant gaps in CGM awareness and access while pointing to growing potential for combining CGM with GLP-1 therapies. Dexcom also partnered with Team Novo Nordisk, an all-diabetic professional cycling team primarily sponsored by Novo Nordisk, underscoring its focus on expanding CGM awareness and adoption.
DXCM’s Industry Prospects
According to Grand View Research, the global CGM devices market size was valued at $13.4 billion in 2025 and is projected to grow beyond $41.4 billion by 2033, at a CAGR of 15.1% from 2026 to 2033.
The primary driver of market growth is the rising global prevalence of diabetes, which has increased demand for more efficient, real-time glucose monitoring solutions.
Updates From DXCM Peers
Abbott Laboratories (ABT - Free Report) recently reported new real-world evidence supporting the benefits of CGM technology, including its FreeStyle Libre systems, for adults with Type 2 diabetes using basal insulin. According to studies, CGM use was associated with a 45% lower risk of death at 12 months and a 36% lower risk at 24 months.
A separate French observational study involving more than 253,000 people with Type 2 diabetes found that Abbott's Libre technology was associated with lower hospitalization rates for acute diabetes-related events across different treatment groups. These findings strengthen the clinical evidence supporting CGM adoption and could help ABT expand the reach of its diabetes care portfolio.
Medtronic (MDT - Free Report) recently completed the exchange-offer process for its diabetes business, MiniMed Group and announced final results on Oct. 14, 2026. The offer was oversubscribed, and Medtronic exchanged its remaining 252.8 million MiniMed shares for approximately 55 million Medtronic ordinary shares. Following the transaction, Medtronic will no longer retain an ownership stake in MiniMed, which is expected to operate as an independent publicly traded company.
The separation marks a strategic shift for Medtronic, allowing it to focus more closely on its remaining medical technology businesses, while MiniMed will pursue growth in diabetes care as a standalone company. The development is relevant to the competitive landscape for diabetes devices, although its longer-term impact will depend on MiniMed's performance as an independent business.
Insulet (PODD - Free Report) announced enhancements to its Omnipod 5 automated insulin delivery system in June 2026, alongside expanded compatibility with Abbott's FreeStyle Libre 3 Plus sensor in the United States. The upgraded algorithm introduces a 100 mg/dL target glucose setting and improved alarm handling, aiming to improve time in range and help users spend more time in automated mode. The expanded sensor compatibility also gives users greater flexibility in choosing their diabetes management technology. Separately, Insulet reported second-quarter 2026 revenues of $801.7 million, up 23.5% year over year, with Omnipod revenue increasing 24.6%.
These developments highlight continued product innovation and commercial momentum, which could support Insulet's growth in automated insulin delivery. However, sustained performance will depend on continued adoption, international expansion and execution in an increasingly competitive diabetes technology market.